Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

220.81 +4.55 (+2.10%)
Official Closing Price Updated: 7:00 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
85 86 Next >
Market Monitor April 28 ( Alphabet, Nvidia & Meta UP, Intel DOWN)
US Markets Rise as Big Tech Shines, Trade Tensions Remain a Concern 
Via Chartmill
Topics World Trade
AbbVie Stock: Q1 Earnings Beat and EPS Outlook Raised
Despite some near-term pressures in aesthetics and legacy products, the overall outlook for 2025 remains positive. 
Via Talk Markets
Topics Earnings Stocks / Equities
4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off
Via The Motley Fool
Topics Economy Intellectual Property World Trade
How Much Would It Take To Earn $100 A Month From AbbVie Stock
 
Via Benzinga
Why AbbVie Stock Topped the Market Today
Via The Motley Fool
Topics Earnings
A Glimpse of AbbVie's Earnings Potential
 
Via Benzinga
Analyst Expectations For AbbVie's Future
 
Via Benzinga
Is the Market Bullish or Bearish on AbbVie?
 
Via Benzinga
Wall Street Rally Pauses, Tesla Heads For Strongest Week In 6 Months: What's Driving Markets Friday?
Wall Street's three-day rally came to a pause on Friday, with major indices hovering near the flatline by midday in New York as caution returned amid mixed signals on U.S.-China trade relations. 
Via Benzinga
AbbVie Raises Profit Outlook But Flags Tariff Risks In Pharma Sector
AbbVie stock climbs after Q1 earnings beat and 2025 EPS forecast raise; strong growth in immunology and neuroscience portfolios led the results. 
Via Benzinga
Topics Earnings
Get insights into the top movers in the S&P500 index of Friday's pre-market session.
Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session. 
Via Chartmill
AbbVie Reports Upbeat Q1 Earnings, Raises 2025 Earnings Forecast: Retail’s Elated
The company’s immunology drugs, Skyrizi and Rinvoq, marked significant revenue growth, offsetting a 50.6% decrease in net revenue from its arthritis drug, Humira. 
Via Stocktwits
Topics World Trade
If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy
AbbVie is well-positioned for industry-leading growth, as Skyrizi and Rinvoq sales outperform, driving system-wide growth alongside a diversified portfolio. 
Via MarketBeat
AbbVie Jumps After Hiking Its Outlook On The Back Of Strong Immunology Sales
The company also raised its outlook for 2025, though noted that guidance hike doesn't include potential pharma sector tariffs. 
Via Investor's Business Daily
Topics Government World Trade
AbbVie (NYSE:ABBV) Reports Bullish Q1
Pharmaceutical company AbbVie (NYSE:ABBV) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 8.4% year on year to $13.34 billion. Its non-GAAP profit of $2.46 per share was 2.6% above... 
Via StockStory
Topics Artificial Intelligence
US Stock Futures Mixed After Three-Day Winning Streak: Expert Dismisses Market Pessimism, Says 'This Isn't Stuff You See In Bear Market'
U.S. stock futures continued to rise on Friday, following a three-day back-to-back winning streak in the regular session, amid growing earnings optimism and the easing of trade tensions between the... 
Via Benzinga
Topics World Trade
Earnings Scheduled For April 25, 2025
 
Via Benzinga
US Futures Gain Amid Back-To-Back Gains On Wall Street, Nikkei Opens In The Green, Dollar Edges Higher
U.S. stock futures are up Thursday night following three back-to-back days in the green during the regular session, amid growing earnings optimism and easing trade tensions. 
Via Benzinga
AbbVie (ABBV) Reports Earnings Tomorrow: What To Expect
Pharmaceutical company AbbVie (NYSE:ABBV) will be reporting earnings tomorrow before market open. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
Bristol Myers' Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides
Bristol Myers' Cobenfy missed its primary endpoint in the Phase 3 ARISE trial but showed symptom improvement in certain subgroups. 
Via Benzinga
Salesforce, AbbVie, Intuitive Surgical And An Industrial Stock On CNBC's 'Final Trades'
 
Via Benzinga
2 High-Yield Dividend Stocks to Buy for Passive Income
Via The Motley Fool
Topics Retirement
AbbVie's Pipeline May Be A 2026 Story, But Analyst Likes The Setup Now
Cantor Fitzgerald starts AbbVie with an Overweight rating and $210 target, citing strong drug growth, low risk, and no major patent concerns. 
Via Benzinga
Topics Intellectual Property
Spotlight on AbbVie: Analyzing the Surge in Options Activity
 
Via Benzinga
This StoneCo Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
 
Via Benzinga
This American Water Works Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Tuesday
 
Via Benzinga
Is AbbVie Stock a Buy?
The pharmaceutical giant has been a roller coaster over the past several months. 
Via The Motley Fool
Topics Government Intellectual Property World Trade
A Congress Member Sold Up To $120K In AbbVie Stock: Here's What You Need To Know
 
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating... 
Via Benzinga
Topics Government
< Previous 1 2 3 4 5 6 7 8 9
...
85 86 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.